Rockwell Medical (RMTI) Cash & Equivalents (2010 - 2026)

Rockwell Medical's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• Quarterly Cash & Equivalents fell 15.64% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (down 15.64% YoY) and the FY2025 annual result came in at $10.7 million, down 31.61% from the prior year.
• Cash & Equivalents was $9.6 million for Q1 2026 at Rockwell Medical, down from $10.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $30.8 million in Q2 2022 and bottomed at $6.6 million in Q1 2024.
• A 5-year average of $12.0 million and a median of $10.9 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 72.25% — and 2024, when it jumped 74.35%.
• Rockwell Medical's Cash & Equivalents stood at $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then surged by 74.35% to $15.7 million in 2024, then plunged by 31.61% to $10.7 million in 2025, then fell by 10.29% to $9.6 million in 2026.
• Business Quant data shows RMTI's Cash & Equivalents at $9.6 million in Q1 2026, $10.7 million in Q4 2025, and $13.6 million in Q3 2025.